Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyene phosphatidylcholine (PPC) is a hepatoprotective agent derived from soy, rich in polyunsaturated fatty acids such as linoleic, linolenic, and oleic acids. It is a major component of cell membrane phospholipids and plays a key role in maintaining membrane integrity and function. PPC exerts its effects through anti-inflammatory, antioxidant, and immunoregulatory mechanisms. Clinically, it is widely used for the treatment of various liver diseases including drug-induced liver injury (DILI), viral hepatitis, nonalcoholic steatohepatitis (NASH), and elevated alanine aminotransferase (ALT) levels. In addition to its hepatoprotective properties, PPC has been shown to enhance cholesterol catabolism and act as an antihyperlipidemic agent[1][4][5][8]. It is commonly used alone or in combination with other liver-protective drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyene phosphatidylcholine.